Clinical Trial

Safety, Tolerability, and Pharmacokinetics of PA9159 Inhalation Aerosol in Healthy Adult Subjects

Completed Phase 1
View on ClinicalTrials.gov →
Summary
PA9159 is a highly potent novel corticosteroid. The purpose of this study is to exam the safety, tolerability, and pharmacokinetics of single and repeat dosing of Inhalation aerosol PA9159, to establish maximum tolerated dose in healthy chinese adult
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-04-07.
Trial Details
NCT Number NCT06916273
Lead Sponsor Anhui Palo Alto Pharmaceuticals, Inc.
Conditions Bronchial Asthma
Enrollment 40 participants
Start Date 2024-07-22
Primary Completion 2024-09-12 (estimated)
Study Completion 2024-09-21 (estimated)
Updated on ClinicalTrials.gov 2025-12-30